These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gaps in Evidence for Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Pelliccia F; Gersh BJ; Camici PG Circulation; 2021 Jan; 143(2):101-103. PubMed ID: 33428428 [No Abstract] [Full Text] [Related]
3. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Wang RS; Rowin EJ; Maron BJ; Maron MS; Maron BA Cardiovasc Res; 2023 May; 119(3):e125-e127. PubMed ID: 37129987 [No Abstract] [Full Text] [Related]
4. Genetics of hypertrophic cardiomyopathy: what is the next step? Kuusisto J Heart; 2020 Sep; 106(17):1291-1292. PubMed ID: 32546508 [No Abstract] [Full Text] [Related]
5. Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. Saberi S; Day SM Circulation; 2018 Jan; 137(5):419-421. PubMed ID: 29378753 [No Abstract] [Full Text] [Related]
6. Update on hypertrophic cardiomyopathy. Marian AJ Tex Heart Inst J; 2010; 37(3):322-3. PubMed ID: 20548812 [No Abstract] [Full Text] [Related]
7. State-of-the-art management of hypertrophic cardiomyopathy in children. Berger S; Dhala A; Dearani JA Cardiol Young; 2009 Nov; 19 Suppl 2():66-73. PubMed ID: 19857352 [No Abstract] [Full Text] [Related]
8. The never ending story of risk stratification for sudden death in hypertrophic cardiomyopathy. Christiaans I; Wilde AA Am J Cardiol; 2011 Jun; 107(12):1871. PubMed ID: 21640227 [No Abstract] [Full Text] [Related]
9. My approach to clinical management of hypertrophic cardiomyopathy. Maron MS Trends Cardiovasc Med; 2014 Oct; 24(7):314-5. PubMed ID: 25218674 [No Abstract] [Full Text] [Related]
10. MY APPROACH to the athlete with hypertrophic cardiomyopathy. Lampert R Trends Cardiovasc Med; 2019 Jul; 29(5):312. PubMed ID: 30928314 [No Abstract] [Full Text] [Related]
11. Hypertrophic Cardiomyopathy, Athlete's Heart, or Both: A Case of Hypertrophic Cardiomyopathy Regression. Kebed KY; Bos JM; Anavekar NS; Mulvagh SL; Ackerman MJ; Ommen SR Circ Cardiovasc Imaging; 2015 Jul; 8(7):e003312. PubMed ID: 26162782 [No Abstract] [Full Text] [Related]
17. Hypertrophic cardiomyopathy: management issues in the new millennium. Thaman R; Firoozi S; Hamid MS; McKenna WJ Curr Cardiol Rep; 2002 May; 4(3):226-32. PubMed ID: 11960592 [TBL] [Abstract][Full Text] [Related]
18. Sex differences in hypertrophic cardiomyopathy: Time to tailor risk stratification and therapy? Constantine A; Dimopoulos K; Rafiq I; Vazir A Eur J Prev Cardiol; 2020 Nov; 27(17):1816-1818. PubMed ID: 31795761 [No Abstract] [Full Text] [Related]
19. Are all non-sustained ventricular tachycardia the same in hypertrophic cardiomyopathy risk stratification for sudden cardiac death? Sabeh MK; Refaat MM J Cardiovasc Electrophysiol; 2020 Aug; 31(8):2099-2100. PubMed ID: 32437027 [No Abstract] [Full Text] [Related]